Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KYTX Kyverna Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: KYTX
Price (delayed)
$2.32
Market cap
$100.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.33
Enterprise value
$11.33M
We are a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our goal is to bring disease-modifying therapeutic benefits to patients suffering from
Highlights
Kyverna Therapeutics's EPS has soared by 96% YoY and by 89% from the previous quarter
Kyverna Therapeutics's debt has decreased by 10% QoQ and by 9% YoY
Kyverna Therapeutics's quick ratio has soared by 190% YoY but it has decreased by 18% from the previous quarter
The net income has dropped by 111% year-on-year and by 15% since the previous quarter
KYTX's equity is down by 12% since the previous quarter
Key stats
What are the main financial stats of KYTX
Market
Valuations
Earnings
Shares outstanding
43.21M
Market cap
$100.26M
Enterprise value
$11.33M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$142.6M
Net income
-$127.48M
EBIT
-$127.34M
EBITDA
-$122.66M
Free cash flow
-$116.46M
Per share
Balance sheet
Liquidity
EPS
-$3.33
EPS diluted
-$3.33
Free cash flow per share
-$3.04
Book value per share
$6.18
Revenue per share
$0
TBVPS
$7.95
Total assets
$304.65M
Total liabilities
$38.06M
Debt
$8.24M
Equity
$266.59M
Working capital
$256.85M
Debt to equity
0.03
Current ratio
8.61
Quick ratio
8.49
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-36.5%
Return on equity
-40.3%
Return on invested capital
-66.5%
Return on capital employed
-47%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KYTX stock price
How has the Kyverna Therapeutics stock price performed over time
Intraday
4.98%
1 week
15.42%
1 month
12.62%
1 year
-84.14%
YTD
-37.97%
QTD
20.21%
Financial performance
How have Kyverna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$142.6M
Net income
-$127.48M
Gross margin
N/A
Net margin
N/A
KYTX's operating income has shrunk by 129% YoY and by 16% QoQ
The net income has dropped by 111% year-on-year and by 15% since the previous quarter
Price vs fundamentals
How does KYTX's price correlate with its fundamentals
Growth
What is Kyverna Therapeutics's growth rate over time
Valuation
What is Kyverna Therapeutics stock price valuation
P/E
N/A
P/B
0.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Kyverna Therapeutics's EPS has soared by 96% YoY and by 89% from the previous quarter
The price to book (P/B) is 71% lower than the last 4 quarters average of 1.3
KYTX's equity is down by 12% since the previous quarter
Efficiency
How efficient is Kyverna Therapeutics business performance
KYTX's ROIC has soared by 69% YoY and by 8% QoQ
The company's return on assets has surged by 57% YoY and by 3.7% QoQ
The company's return on equity rose by 21% QoQ
Dividends
What is KYTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KYTX.
Financial health
How did Kyverna Therapeutics financials performed over time
Kyverna Therapeutics's quick ratio has soared by 190% YoY but it has decreased by 18% from the previous quarter
The current ratio has soared by 182% YoY but it has contracted by 18% from the previous quarter
Kyverna Therapeutics's debt is 97% lower than its equity
KYTX's debt to equity has soared by 143% YoY
KYTX's equity is down by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.